This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of renal pelvis
C3_RENAL_PELVIS
renal pelvis carcinoma: A carcinoma arising in the renal pelvis. The majority of renal pelvis carcinomas are transitional cell and less frequently squamous cell carcinomas.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
253 |
4. Check minimum number of eventsNone |
253 |
5. Include endpointsNone |
253 |
6. Filter based on genotype QC (FinnGen only) |
228 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of renal pelvis
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of renal pelvis, including Hilmo
- Malignant neoplasm of urinary organs
- Malignant neoplasm of urinary organs, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 228 | 60 | 168 |
| Unadjusted period prevalence (%) | 0.06 | 0.02 | 0.08 |
| Median age at first event (years) | 72.34 | 71.83 | 72.52 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 235
- Matched controls
- 2350
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
287.3
213
*
8120/3-C65.9
ICD-O-3
Transitional cell carcinoma, NOS, of renal pelvis
+∞
264.2
201
*
UKC02
NOMESCO Finland
Cystoscopy
36.5
162.8
192
256
R31
ICD-10 Finland
Unspecified haematuria
19.6
124.4
148
188
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
50.3
104.8
63
17
H02AB02
ATC
dexamethasone; systemic
60.4
91.0
52
11
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
88.2
79
*
D41.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Renal pelvis
1176.1
86.3
79
*
130
Kela drug reimbursment
Malignant tumour
+∞
82.2
74
*
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
37.1
77.2
50
17
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
71.6
65
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
70.4
64
*
JN4AD
NOMESCO Finland
Body CT examination
13.0
63.2
71
76
Z51.5
ICD-10 Finland
Palliative care
13.2
59.7
65
66
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
54.3
50
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
22.4
53.0
41
22
A03FA01
ATC
metoclopramide; systemic, rectal
8.4
49.8
83
144
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
47.5
44
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
113.8
43.6
46
5
B01AB10
ATC
tinzaparin; parenteral
8.4
40.6
62
96
A04AA02
ATC
granisetron; systemic, transdermal
+∞
38.6
36
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
432.1
38.2
37
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
12.8
36.5
38
35
UKB02
NOMESCO Finland
Retrograde ureteroscopy
87.1
34.0
37
5
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
386.0
33.8
33
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
32.0
30
*
XX3DW
NOMESCO Finland
Time consuming IT work
10.8
31.8
37
40
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
99.0
31.7
34
*
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
28.7
27
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
28.7
27
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
317.2
28.4
28
*
JN4BD
NOMESCO Finland
Extensive body CT
9.2
28.1
37
47
N02AA05
ATC
oxycodone; systemic
4.7
26.4
82
241
C61
ICD-10 Finland
Malignant neoplasm of prostate
290.9
26.2
26
*
KH1AD
NOMESCO Finland
CT of urinary organs
9.9
26.0
32
37
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
52.7
23.9
28
6
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
23.3
22
*
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
88.8
22.1
24
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.7
21.8
62
168
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.9
21.5
56
141
A04AA01
ATC
ondansetron; systemic, rectal
19.6
20.7
31
18
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.7
20.6
43
89
B02AA02
ATC
tranexamic acid; systemic
5.7
20.1
42
87
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
57.3
18.3
21
*
C64
ICD-10 Finland
Malignant neoplasm of kidney, except renal pelvis
+∞
17.9
17
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
17.9
17
*
8000/3-C65.9
ICD-O-3
Neoplasm, malignant of renal pelvis
+∞
17.9
17
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.4
17.0
85
336
L03AA02
ATC
filgrastim; parenteral
+∞
16.9
16
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
16.9
16
*
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
15.8
15
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
15.8
15
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.1
15.6
50
146
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
31.0
15.5
20
7
U06
ICPC
Haematuria
13.1
15.0
26
22
B01AB05
ATC
enoxaparin; parenteral
3.1
15.0
95
427
KC1GB
NOMESCO Finland
Cystography with X-ray
85.6
14.8
16
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
14.7
14
*
KAC10
NOMESCO Finland
Total nephrectomy with capsule
+∞
14.7
14
*
116
Kela drug reimbursment
Prostate cancer
+∞
14.7
14
*
JN4CD
NOMESCO Finland
Very extensive body CT
25.7
14.0
19
8
GD1AD
NOMESCO Finland
Thorax CT examination
5.2
14.0
31
67
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
13.7
13
*
7126
FHL
Nephroureterectomy
+∞
13.7
13
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
13.7
13
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
13.7
13
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
6.4
13.3
23
39
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.0
13.2
42
121
WX408
NOMESCO Finland
General anesthesy, balanced
3.1
13.1
73
302
WX402
NOMESCO Finland
General anaesthesia
3.3
12.9
58
211
ZX136
NOMESCO Finland
Intravesicalis
+∞
12.6
12
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
12.6
12
*
KAB00
NOMESCO Finland
Biopsy of kidney or pelvis of kidney
+∞
12.6
12
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
11.0
12.3
23
23
1891C
ICD-9 Finland
Malignant neoplasm of kidney and other and unspecified urinary organs, Renal pelvis[NEOPLASMA MALIGNUM PELVIS RENIS,MUU/TARK MÄÄR SYÖPÄ]
+∞
11.5
11
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
9.2
10.8
22
26
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
62.9
10.7
12
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
15.2
10.7
17
12
J01EA01
ATC
trimethoprim; systemic
2.8
10.5
68
301
R82.8
ICD-10 Finland
Abnormal findings on cytological and histological examination of urine
+∞
10.5
10
*
WC305
NOMESCO Finland
Simple therapy of local tumor recidive with biomodifiers
+∞
10.5
10
*
J01MA02
ATC
ciprofloxacin; systemic
2.5
10.4
117
675
WW500
NOMESCO Finland
Blood transfusion
11.4
10.0
18
17
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
57.4
9.7
11
*
KAC11
NOMESCO Finland
Total nephrectomy with capsule, transcutaneous
104.0
9.5
10
*
KC1GD
NOMESCO Finland
CT cystography of bladder
104.0
9.5
10
*
XKD00
NOMESCO Finland
Uroflowmetry
2.7
9.5
64
288
U75
ICPC
Malignant neoplasm of kidney
+∞
9.4
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.4
9
*
8130/2-C65.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of renal pelvis
+∞
9.4
9
*
115
Kela drug reimbursment
Breast cancer
+∞
9.4
9
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
9.4
9
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
9.4
9
*
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
+∞
9.4
9
*
8130/2-C67.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of bladder, NOS
+∞
9.4
9
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.1
8.9
17
18
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.8
8.8
28
80
KH1BD
NOMESCO Finland
Extensive urinary tract CT examination
52.0
8.7
10
*
WZC30
NOMESCO Finland
Teaching
3.1
8.7
40
146
KCW96
NOMESCO Finland
Other operations on bladder
28.7
8.6
11
*
L02AE02
ATC
leuprorelin; implant, parenteral
93.3
8.5
9
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
8.4
8
*
KA3GB
NOMESCO Finland
Retrograde pyelography
+∞
8.4
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.9
8.2
43
169
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
34.7
8.1
10
*
R50.9
ICD-10 Finland
Fever, unspecified
2.8
8.0
45
183
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
13.7
8.0
13
10
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.6
7.9
55
249
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
7.8
133
880
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
7.8
63
307
TKC20
NOMESCO Finland
Catheterisation of bladder
3.2
7.6
32
110
ZXE20
NOMESCO Finland
More than three and less than five hours
2.8
7.5
42
170
N02AX02
ATC
tramadol; systemic, rectal
2.1
7.5
116
736
WF002
NOMESCO Finland
Radical radiotherapy
82.6
7.5
8
*
KBB00
NOMESCO Finland
Biopsy of ureter
+∞
7.3
7
*
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
+∞
7.3
7
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
7.3
7
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
+∞
7.3
7
*
A06AH03
ATC
naloxegol; oral
31.1
7.2
9
*
N30.0
ICD-10 Finland
Acute cystitis
2.7
7.2
42
174
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.6
7.1
17
39
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.2
7.0
30
104
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
41.3
6.8
8
*
WX725
NOMESCO Finland
Noninvasive ventilation
3.7
6.7
22
64
1530
FHL
Urethrocystoscopy
6.0
6.6
17
30
KA1AE
NOMESCO Finland
Kidney ultrasound examination
7.8
6.5
14
19
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.8
6.5
34
133
KH1DD
NOMESCO Finland
CT urography of urinary organs
71.7
6.5
7
*
K43.9
ICD-10 Finland
Other and unspecified ventral hernia without obstruction or gangrene
6.3
6.4
16
27
J01MA12
ATC
levofloxacin; systemic
2.3
6.3
57
289
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
+∞
6.3
6
*
PJD53
NOMESCO Finland
Block dissection of aortic lymph nodes
+∞
6.3
6
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
6.3
6
*
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
+∞
6.3
6
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
6.3
6
*
KAD52
NOMESCO Finland
Retrograde ureteronephroscopic destruction of tumour of pelvis of kidney
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
C67
ICD-10 Finland
Malignant neoplasm of bladder
+∞
6.3
6
*
L02BG04
ATC
letrozole; oral
+∞
6.3
6
*
PJD43
NOMESCO Finland
Excision of aortic lymph nodes
+∞
6.3
6
*
7321
FHL
TU biopsy, coagulation or laser
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
KCD30
NOMESCO Finland
Destruction of tumour of bladder
+∞
6.3
6
*
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
6.3
6
*
ZX120
NOMESCO Finland
Intravenous
3.3
6.1
24
79
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
149
695
4.13
24.93
8.4
3.1
—
—
—
0
0
126
629
3.16
16.93
9.0
3.2
130.79
168.99
e6/l
0.13
108
482
100
446
3.16
16.20
5.4
2.3
3.06
4.19
e6/l
1.16
89
406
139
754
3.06
15.79
3.9
2.5
—
—
estimate
—
0
0
40
99
4.66
15.43
2.4
1.3
58.58
2.82
ug/l
0.51
32
75
111
541
2.99
15.15
9.3
3.0
0.30
0.45
e6/l
0.67
94
396
153
918
2.91
13.72
10.4
3.7
8.71
12.77
umol/l
11.03
153
862
71
297
2.99
12.39
10.1
6.2
104.66
104.47
mmol/l
0.11
71
297
140
834
2.68
12.20
6.3
3.7
32.64
34.92
g/l
4.20
131
769
66
271
3.00
11.85
9.6
6.5
5.20
5.04
kpa
0.81
61
264
66
271
3.00
11.85
9.6
6.5
13.44
11.19
kpa
2.62
61
265
86
412
2.71
11.53
3.1
2.1
—
—
—
0
0
142
879
2.56
11.02
10.1
5.6
1.19
1.21
mmol/l
1.07
134
793
152
981
2.56
10.64
10.4
6.1
1.19
1.21
mmol/l
1.15
130
840
63
269
2.83
10.41
9.9
6.5
-0.99
1.05
mmol/l
2.60
47
219
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
26
64
4.44
9.99
2.9
2.4
0.39
0.42
iu/ml
0.09
17
30
144
925
2.44
9.91
13.6
5.2
4.78
4.52
e9/l
0.41
124
792
16
13
13.10
9.51
1.3
1.2
45.87
26.72
ng/l
0.65
16
13
69
329
2.55
9.05
9.7
2.9
2.45
1.23
e6/l
0.72
51
165
162
1136
2.37
8.58
8.0
4.8
6.80
6.94
mmol/l
0.51
153
1081
28
87
3.52
7.81
1.6
1.7
3.27
2.78
ug/l
0.08
21
71
62
315
2.32
6.88
10.3
3.1
0.93
2.67
e6/l
1.87
43
151
97
613
1.99
6.01
5.7
2.0
2.34
2.35
mmol/l
0.39
87
530
39
170
2.55
6.01
3.9
2.7
0.13
0.41
e6/l
1.92
39
162
36
154
2.58
5.75
3.9
3.7
88.84
91.02
ng/l
0.05
30
127
132
949
1.89
5.39
6.8
4.2
0.00
0.03
estimate
0.65
34
190
58
317
2.10
5.27
2.4
2.4
2.05
2.20
g/l
1.19
53
292
61
346
2.03
4.99
2.5
2.5
10.23
12.50
umol/l
1.64
56
323
15
42
3.75
4.85
1.3
1.2
—
—
—
0
0
20
68
3.12
4.84
1.8
1.3
41.60
50.10
mg/l
0.53
15
61
20
68
3.12
4.84
1.8
1.3
45.67
34.68
mg/l
0.68
15
62
126
924
1.78
4.55
6.5
4.1
0.00
0.00
estimate
-0.00
33
197
18
60
3.17
4.50
1.8
1.3
1.16
1.51
ratio
—
9
38
31
139
2.42
4.48
1.9
1.6
—
—
—
0
0
15
45
3.49
4.40
2.6
1.9
1.75
1.87
mg/l
0.25
15
35
127
940
1.76
4.38
6.7
4.1
0.00
0.00
estimate
-0.00
34
203
47
269
1.93
3.69
2.5
1.8
—
—
—
0
0
82
561
1.71
3.58
2.1
2.3
2.70
2.94
mg/l
0.47
69
464
6
6
10.22
3.51
1.0
1.7
—
—
—
0
0
6
6
10.22
3.51
1.0
1.7
—
—
—
0
0
59
370
1.79
3.47
2.4
1.8
—
—
—
0
0
13
38
3.56
3.37
1.2
1.2
—
—
—
0
0
43
249
1.89
3.25
4.7
3.3
5.89
5.81
kpa
0.21
38
241
11
29
3.93
3.23
1.3
1.2
—
—
—
0
0
79
548
1.67
3.22
7.2
4.1
0.00
0.00
estimate
-0.00
25
179
12
35
3.56
3.15
1.3
1.2
—
—
—
0
0
47
286
1.80
3.04
2.5
1.7
—
—
—
0
0
65
435
1.68
3.01
5.2
4.5
123.99
448.44
ng/l
1.48
56
380
26
129
2.14
3.00
3.0
2.0
41.47
59.57
ml/min/173m2
2.39
15
51
61
403
1.69
2.96
3.9
2.1
2.50
2.45
mmol/l
2.54
54
349
13
47
2.87
2.86
1.1
1.3
—
—
—
0
0
18
78
2.42
2.82
4.3
3.7
—
—
—
0
0
6
11
5.56
2.56
3.2
3.2
0.67
0.91
index
—
6
11
15
64
2.44
2.44
1.2
1.4
—
—
—
0
0
68
484
1.57
2.42
5.6
3.7
13.16
0.01
estimate
0.48
19
153
12
46
2.70
2.40
1.2
1.4
—
—
—
0
0
40
249
1.73
2.39
4.9
3.2
1.87
1.92
mmol/l
0.02
27
210
24
132
1.91
2.13
6.0
3.7
2.12
2.15
mmol/l
0.01
17
99
118
965
1.45
2.08
4.8
4.5
1.99
2.14
ug/l
0.29
92
851
92
723
1.45
1.98
7.3
4.1
0.00
0.00
estimate
-0.00
24
152
5
11
4.62
1.95
1.2
1.1
—
—
—
0
0
65
492
1.44
1.68
3.1
2.7
415.66
373.80
umol/l
1.93
58
418
22
131
1.75
1.56
2.5
1.6
—
—
—
0
0
148
1301
1.37
1.53
4.8
4.4
20.60
13.21
mm/h
3.56
133
1180
10
46
2.23
1.42
1.2
1.4
—
—
—
0
0
30
201
1.56
1.38
5.1
3.4
—
—
—
0
0
5
17
2.98
1.36
1.0
1.5
—
—
—
0
0
9
42
2.19
1.35
1.4
1.4
—
—
—
0
0
6
24
2.54
1.31
1.2
1.5
—
—
—
0
0
82
671
1.34
1.31
2.1
2.3
139.16
267.60
u/l
1.65
76
625
6
25
2.44
1.25
4.7
5.0
14.60
12.68
mg/l
—
6
25
92
773
1.31
1.21
3.2
2.9
235.30
141.93
ug/l
1.86
82
696
8
39
2.09
1.16
1.4
2.0
76.25
86.82
%
—
8
39
9
46
1.99
1.05
1.2
1.4
—
—
—
0
0
116
1020
1.27
1.04
3.3
3.2
61.64
55.13
u/l
0.24
110
934
63
517
1.30
0.96
3.6
3.0
0.82
0.79
ug/l
0.12
40
353
6
27
2.25
0.94
1.0
1.3
—
—
—
0
0
6
27
2.25
0.94
2.5
2.0
8.67
10.52
mmol/l
—
6
27
17
111
1.57
0.90
1.4
1.5
—
—
—
0
0
6
30
2.03
0.87
1.7
3.1
6.60
13.96
pmol/l
—
6
30
58
694
0.78
0.86
1.8
2.0
1.52
1.28
mmol/l
1.34
49
551
6
31
1.96
0.85
4.0
1.5
—
—
—
0
0
139
1267
1.24
0.85
4.7
3.7
15.20
15.16
pmol/l
0.08
125
1117
88
766
1.24
0.82
4.6
4.1
24.20
24.73
%
0.12
42
375
8
48
1.69
0.79
1.1
1.2
—
—
—
0
0
100
886
1.22
0.78
4.5
4.5
46.06
84.74
ng/l
0.52
89
712
6
34
1.78
0.77
1.2
1.4
—
—
—
0
0
57
477
1.26
0.75
1.7
1.9
390.28
401.12
pmol/l
0.14
40
381
5
24
2.11
0.75
1.4
1.5
—
—
—
0
0
55
459
1.26
0.74
8.1
4.2
1.02
1.02
kg/l
0.01
46
299
24
318
0.73
0.74
1.1
1.3
0.62
1.95
u/ml
—
6
85
27
207
1.34
0.67
4.0
2.8
4.16
4.44
kpa
0.33
22
197
183
1741
1.23
0.63
17.5
10.6
22.24
25.46
u/l
2.54
178
1665
8
51
1.59
0.61
2.0
1.4
—
—
—
0
0
11
72
1.55
0.60
1.3
1.3
12.66
10.61
g/l
0.29
11
59
84
758
1.17
0.51
4.1
4.2
20.64
9.27
mg/mmol
1.01
59
493
44
380
1.19
0.44
1.7
1.6
1.98
1.36
mg/l
0.56
39
299
11
78
1.43
0.44
2.5
1.6
—
—
—
0
0
12
87
1.40
0.43
1.2
1.3
8.40
7.54
g/l
0.57
12
74
12
87
1.40
0.43
1.2
1.3
4.11
3.74
g/l
0.30
12
74
12
87
1.40
0.43
1.3
1.3
4.22
4.14
g/l
0.14
12
74
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
159.36
—
0
18
51
451
1.17
0.40
1.8
1.8
1182.22
1176.44
nmol/l
0.01
40
347
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
22
265
0.81
0.36
1.3
1.3
120.50
37.30
iu/ml
—
10
84
10
73
1.39
0.35
2.7
1.5
—
—
—
0
0
157
1631
0.89
0.34
8.1
7.7
39.96
40.97
mmol/mol
0.92
139
1504
185
1794
1.15
0.34
49.2
24.9
4.13
4.46
e12/l
12.23
180
1729
6
47
1.28
0.32
1.3
1.3
—
—
—
0
0
162
1677
0.89
0.32
5.7
6.6
2.27
2.44
mmol/l
1.76
143
1512
150
1557
0.90
0.30
4.3
4.7
1.31
1.26
mmol/l
0.55
133
1382
83
775
1.11
0.29
2.9
2.2
—
—
—
0
0
5
73
0.68
0.26
1.2
2.1
48.20
42.49
nmol/l
—
5
68
21
244
0.85
0.25
1.2
1.3
1.77
16.12
u/ml
—
6
75
100
951
1.09
0.24
2.3
2.3
94.86
94.15
pmol/l
0.07
58
498
159
1636
0.91
0.23
5.0
5.7
4.10
4.29
mmol/l
1.64
143
1492
28
248
1.15
0.23
12.9
8.0
—
—
—
0
0
7
93
0.75
0.23
3.4
2.4
3.53
3.52
ratio
—
7
80
5
40
1.26
0.22
1.0
1.5
—
—
—
0
0
158
1624
0.92
0.22
4.9
5.5
1.30
1.41
mmol/l
2.55
142
1461
164
1596
1.09
0.22
36.6
16.4
56.17
71.82
ml/min/173m2
18.33
157
1484
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
163
1666
0.93
0.17
6.1
5.7
6.04
6.19
mmol/l
0.90
143
1476
18
160
1.14
0.14
1.7
2.5
10.55
14.93
nmol/l
1.53
18
146
10
85
1.18
0.12
1.3
1.3
3.50
2.94
g/l
—
10
72
23
251
0.91
0.12
4.4
5.2
31.00
32.65
%
0.21
12
155
80
775
1.05
0.10
2.2
2.5
75.09
78.29
nmol/l
0.53
69
660
6
58
1.04
0.08
1.0
1.2
—
—
—
0
0
15
137
1.10
0.07
1.0
1.3
—
—
—
0
0
9
87
1.04
0.07
1.3
1.3
—
—
—
0
0
16
153
1.05
0.01
1.5
1.5
—
—
—
0
0
156
1559
1.00
0.00
6.3
4.9
1.89
2.01
mu/l
0.50
145
1374
66
655
1.01
0.00
1.8
1.8
16.00
19.73
nmol/l
1.39
57
542
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
13.33
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
10.29
—
0
6
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
12.35
—
0
6
0
8
0.00
-0.00
0.0
2.0
—
60.44
—
0
8
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
36.61
—
0
9
0
5
0.00
-0.00
0.0
7.2
—
10.82
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
10.17
—
0
6
6
66
0.91
-0.00
2.8
2.2
2.80
3.44
mmol/l
—
6
55
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_RENAL_PELVIS – Malignant neoplasm of renal pelvis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).